Clascoterone Shows Favorable Efficacy, Safety in Phase III Trials

Novel androgen receptor inhibitor cream also had low, mostly mild adverse events Use of the novel topical androgen receptor inhibitor, clascoterone cream 1%, was associated with favorable efficacy and safety profiles compared to...